-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Pliant Therapeutics, Lowers Price Target to $1.5

Benzinga·03/04/2025 17:15:43
Listen to the news
Citigroup analyst David Lebowitz maintains Pliant Therapeutics (NASDAQ:PLRX) with a Neutral and lowers the price target from $4 to $1.5.